Article
Expression of immune check point gene TIM‑3 in patients newly diagnosed with acute myeloid leukemia: Significance and impact on outcome
24 Feb 2021
Abstract excerpt
Despite recent advancements in the therapeutic landscape of acute myeloid leukemia (AML), the prognosis of patients remains poor. Immune check point inhibitors have been investigated in hematological malignancies, including AML; however, the role of T-cell immunoglobulin and mucin domain 3 (TIM-3) in AML has not yet been fully elucidated. Thus, the present study aimed to investigate TIM-3 gene expression in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
